Vivitrol News and Research

RSS

Vivitrol is a drug that blocks the action of opiates (drugs used to treat pain). It may be used in the treatment of intravenous opiate addiction or alcohol dependence. Vivitrol is also being studied in the treatment of breast cancer. It may block the effects of the hormone estrogen, which causes some breast cancer cells to grow, or block the blood flow to tumors. It is a type of opiate antagonist. Also called naltrexone, naltrexone hydrochloride, and ReVia.

Health on wheels: Tricked-out RVs deliver addiction treatment to rural communities

Tonja Jimenez is far from the only person driving an RV down Colorado's rural highways. But unlike the other rigs, her 34-foot-long motor home is equipped as an addiction treatment clinic on wheels, bringing lifesaving treatment to the northeastern corner of the state, where patients with substance use disorders are often left to fend for themselves.

28 Sep 2020

In tiny doses, an addiction medication moonlights as treatment for chronic pain

Lori Pinkley, a 50-year-old from Kansas City, Mo., has struggled with puzzling chronic pain since she was 15.

26 Sep 2019

Over 1 million years of life lost in Ohio from overdose deaths, shows study

The drug addiction epidemic continues to plague the country, and thousands of lives are cut short each year due to overdose.

18 Jul 2019

Study: Dozens of counties in the U.S. are at highest risk for opioid deaths

Dozens of counties in the Midwest and South are at the highest risk for opioid deaths in the United States, say University of Michigan researchers.

29 Jun 2019

$1.5 million grant to develop opioid treatment program for jail detainees

In what could serve as a model for tackling one of the nation's top public health crises, a University of Massachusetts Amherst epidemiology researcher is teaming up with two Western Massachusetts sheriff's offices to design, implement and study an opioid treatment program for jail detainees in Franklin and Hampshire counties.

22 Feb 2019

Study finds rapid increase in overdose deaths involving amphetamines and methamphetamines

The number of overdose deaths involving methamphetamines and amphetamines in the state of Ohio increased more than 5,000 percent over the course of eight years, according to data collected by the Ohio Alliance for Innovation in Population Health.

7 Nov 2018

After opioid overdose, only 30 percent get medicine to treat addiction

More than 115 Americans die every day of opioid overdose. Many more survive thanks to the antidote medication, naloxone. But a study out Monday finds that just 3 in 10 patients revived by an EMT or in an emergency room received the follow-up medication known to avoid another life-threatening event.

19 Jun 2018

People in recovery worry GOP Medicaid cuts would put treatment out of reach

Republicans in both the House and the Senate are considering big cuts to Medicaid. But those cuts endanger addiction treatment, which many people receive through the government health insurance program.

14 Jun 2017

BMC opens new opioid urgent care center to treat patients with substance use disorders

Boston Medical Center, in collaboration with the Massachusetts Department of Public Health and the Boston Public Health Commission, has launched a new opioid urgent care center to give patients with substance use disorders rapid access to a full continuum of treatment services.

18 Oct 2016

Mass. to spend $20 million to combat opioid use

Governor Deval Patrick announced the plan Tuesday that will also team with five other New England states to upgrade treatment and expand coverage abuse of the drugs.

12 Jun 2014

Alkermes reports financial results for first quarter of 2014

Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and enabling us to invest in our advancing late-stage pipeline and prepare for the launch of aripiprazole lauroxil," commented James Frates, Chief Financial Officer of Alkermes.

30 Apr 2014

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute.

4 Nov 2013

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on a calendar year basis.

31 Oct 2013

Positive results from Alkermes VIVITROL addiction study

Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV.

10 Nov 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.

15 Jun 2011

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.

9 May 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 alcohol dependent patients.

9 Dec 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010